Sickle Cell Disease PKR Activators Competition
PKR Candidates, FT-4202 & Mitapivat established proof of concept in Phase I trials
Agios’s PKR Activator, Mitapivat’s strategy for Sickle Cell Disease (SCD)
Agios Pharmaceuticals, shared the proof of clinical concept that has been established based on preliminary analysis in the phase 1 study of mitapivat (AG-348) in patients with sickle cell anemia. We, Mellalta Meets would like […]